BioView, Transgenomic combine for in-vitro distribution pact:
This article was originally published in Clinica
Executive Summary
Rehovot, Israel-based cell imaging specialist BioView is expanding its European sales penetration by combining with biotechnology company Transgenomic to distribute its scanning and analysis workstations in western Europe and Scandinavia. BioView's products, including its Duet, Allegro and Accord automated workstations, will be marketed, sold and serviced through Transgenomic's European sales force. BioView had previously sold its Duet system to university hospitals and commercial laboratories in the US and Europe through its own sales force. The company's automated scanning microscopes and image analysis systems are designed for in-vitro diagnostic use - particularly to aid the detection, classification and counting of cells for haematological, breast cancer, bladder cancer, and prenatal and postnatal genetic testing. Transgenomic (Omaha, Nebraska) said that the deal proved to be complementary to its existing line of cytogenetics products for genetic variation and mutation analysis. Financial terms of the deal were not disclosed.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.